| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Neomangiferin targets inflammatory signaling pathways including NF-κB and MAPKs. It modulates the Th17/Treg balance. The compound regulates glucose and lipid metabolism and improves insulin sensitivity. By suppressing inflammatory signaling pathways, Neomangiferin exerts anti-inflammatory, antidiabetic, and antiosteoporotic effects. It also has antioxidant and neuroprotective activities.
|
|---|---|
| ln Vitro |
In vitro, Neomangiferin exhibits antidiabetic and antiosteoporotic actions. It has antioxidant, antitumor, and neuroprotective effects. The compound regulates glucose and lipid metabolism and improves insulin sensitivity in cell-based assays. It suppresses inflammatory signaling pathways including NF-κB and MAPKs. Detailed in vitro data are available in the primary literature.
|
| ln Vivo |
In vivo, Neomangiferin has beneficial effects on high-fat diet-induced nonalcoholic fatty liver disease in rats. It modulates the Th17/Treg balance and ameliorates colitis in mice. The compound exhibits antidiabetic and antiosteoporotic actions in vivo. It regulates glucose and lipid metabolism. Neomangiferin is a natural product with diverse biological activities.
|
| Enzyme Assay |
In vitro anti-inflammatory assays for Neomangiferin typically use LPS-stimulated macrophages (e.g., RAW264.7). Cells are cultured in DMEM with 10% FBS. Cells are seeded in 96-well plates and pre-treated with Neomangiferin at various concentrations (0.1-100 μM) for 1-2 hours, followed by LPS stimulation for 24 hours. Pro-inflammatory cytokine levels (TNF-α, IL-6, IL-1β) are measured by ELISA. NF-κB and MAPK signaling is assessed by Western blotting. Nitric oxide production is measured by Griess assay. IC₅₀ values are calculated from dose-response curves. Controls include vehicle and known anti-inflammatory compounds.
|
| Cell Assay |
For cell-based assays, relevant cell lines (e.g., macrophages, hepatocytes, osteoblasts) are cultured in appropriate medium. Cells are seeded in multi-well plates and treated with Neomangiferin at various concentrations for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo. Gene expression of inflammatory markers, glucose metabolism genes, and osteogenic markers is analyzed by RT-PCR. Cytokine levels are measured by ELISA. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Neomangiferin is typically administered orally to rodents. The compound is formulated in a suitable vehicle such as 0.5% methylcellulose or saline. For NAFLD models, rats are fed a high-fat diet with or without Neomangiferin supplementation. For colitis models, mice are treated with dextran sulfate sodium (DSS) and Neomangiferin. Endpoints include liver histology, serum ALT/AST levels, inflammatory cytokine levels, and Th17/Treg balance assessment. Blood and tissue samples are collected for analysis. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Neomangiferin (MW 584.48, C₂₅H₂₈O₁₆) is a naturally occurring C-glucosyl xanthone. It shows a purity of ≥99%. The compound is a pale yellow powder. Detailed pharmacokinetic parameters are not extensively reported in publicly available sources. The compound is typically stored at -20°C. Further ADME studies are needed to fully characterize its pharmacokinetic profile. The compound is for research purposes.
|
| Toxicity/Toxicokinetics |
Toxicology data for Neomangiferin are limited in publicly available sources. As a natural product, potential effects on inflammation and metabolism should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Neomangiferin is a type of flavonoid compound. It has been reported that neomangiferin is found in Anemarrhena asphodeloides and Lithospermum erythrorhizon, and relevant data are available for reference.
Neomangiferin is a research-grade natural xanthone glycoside for studying inflammation, diabetes, and metabolic disorders. Its primary applications include inflammation research, diabetes research, and natural products research. The compound is not approved for clinical use and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves suppression of inflammatory signaling pathways (NF-κB, MAPKs) and regulation of glucose and lipid metabolism. |
| Molecular Formula |
C25H28O16
|
|---|---|
| Molecular Weight |
584.4802
|
| Exact Mass |
584.138
|
| CAS # |
64809-67-2
|
| PubChem CID |
6918448
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.839
|
| Boiling Point |
1026.377ºC at 760 mmHg
|
| Flash Point |
343.913ºC
|
| Index of Refraction |
1.76
|
| LogP |
-2.2
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
41
|
| Complexity |
924
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=C2C(=CC(=C1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)OC4=C(C2=O)C(=C(C(=C4)O)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O
|
| InChi Key |
VUWOVGXVRYBSGI-IRXABLMPSA-N
|
| InChi Code |
InChI=1S/C25H28O16/c26-4-12-17(31)20(34)22(36)24(39-12)14-8(29)3-11-15(19(14)33)16(30)6-1-10(7(28)2-9(6)38-11)40-25-23(37)21(35)18(32)13(5-27)41-25/h1-3,12-13,17-18,20-29,31-37H,4-5H2/t12-,13-,17-,18-,20+,21+,22-,23-,24+,25-/m1/s1
|
| Chemical Name |
1,3,6-trihydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-7-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyxanthen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~171.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7109 mL | 8.5546 mL | 17.1092 mL | |
| 5 mM | 0.3422 mL | 1.7109 mL | 3.4218 mL | |
| 10 mM | 0.1711 mL | 0.8555 mL | 1.7109 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
